title: A bacterial interference strategy for prevention of UTI in persons practicing intermittent catheterization.
abstract: METHODS
  Non-randomized pilot trial.
  
  
  OBJECTIVE
  To determine whether Escherichia coli 83972-coated urinary catheters in persons with spinal cord injury (SCI) practicing an intermittent catheterization program (ICP) could (1) achieve bladder colonization with this benign organism and (2) decrease the rate of symptomatic urinary tract infection (UTI).
  
  
  METHODS
  Outpatient SCI clinic in a Veterans Affairs hospital (USA).
  
  
  METHODS
  Participants had neurogenic bladders secondary to SCI, were practicing ICP, had experienced at least one UTI and had documented bacteruria within the past year. All participants received a urinary catheter that had been pre-inoculated with E. coli 83972. The catheter was left in place for 3 days and then removed. Participants were followed with urine cultures and telephone calls weekly for 28 days and then monthly until E. coli 83972 was lost from the urine. Outcome measures were (1) the rate of successful bladder colonization, defined as the detection (>or=10(2) cfu ml(-1)) of E. coli 83972 in urine cultures for >3 days after catheter removal and (2) the rate of symptomatic UTI during colonization with E. coli 83972.
  
  
  RESULTS
  Thirteen participants underwent 19 insertions of study catheters. Eight participants (62%) became successfully colonized for >3 days after catheter removal. In these 8 participants, the rate of UTI during colonization was 0.77 per patient-year, in comparison with the rate of 2.27 UTI per patient-year before enrollment.
  
  
  CONCLUSIONS
  E. coli 83972-coated urinary catheters are a viable means of achieving bladder colonization with this potentially protective strain in persons practicing ICP.
authors.affiliation: Department of Internal Medicine, New York Medical College-Westchester Medical Center, Westchester, NY, USA.
authors.forename: A
authors.initials: A
authors.lastname: Prasad
authors.forename: M E
authors.initials: ME
authors.lastname: Cevallos
authors.forename: S
authors.initials: S
authors.lastname: Riosa
authors.forename: R O
authors.initials: RO
authors.lastname: Darouiche
authors.forename: B W
authors.initials: BW
authors.lastname: Trautner
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002408:Catheters, Indwelling / Q000382:microbiology*; D004926:Escherichia coli; D004927:Escherichia coli Infections / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D010865:Pilot Projects; D013119:Spinal Cord Injuries / Q000150:complications* / Q000628:therapy; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000209:etiology / Q000628:therapy; D014546:Urinary Catheterization / Q000009:adverse effects*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000209:etiology* / Q000517:prevention & control*; D014728:Veterans
chemical_list: D000900:Anti-Bacterial Agents